Mark Elliott Boulding, Executive VP AND CLO at PTC THERAPEUTICS, INC. (PTCT), sold 31,042 shares at $53.31 ($1.7M) on 2025-03-12, disclosed to the SEC on 2025-03-14.
Scheduled sale ($1.7M) by Executive VP AND CLO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $53.23 | 2,395 | $127K | 7.7% |
| 2 | $53.23 | 2,395 | $127K | 7.7% |
| 3 | $53.31 | 13,126 | $700K | 42.3% |
| 4 | $53.31 | 13,126 | $700K | 42.3% |
| Total | $53.30 avg | 31,042 | $1.7M | 100% |
| Filing → |
| PTCT | SELL | 2026-08-19 | $204K | — | Filing → |
| PTCT | SELL | 2026-07-08 | $432K | — | Filing → |
| PTCT | SELL | 2026-06-22 | $823K | — | Filing → |